Ildong Pharmaceutical Statistics

Total Valuation

Ildong Pharmaceutical has a market cap or net worth of KRW 305.86 billion. The enterprise value is 444.98 billion.

Market Cap	305.86B
Enterprise Value	444.98B

Important Dates

The next estimated earnings date is Friday, February 7, 2025.

Earnings Date	Feb 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Ildong Pharmaceutical has 27.93 million shares outstanding. The number of shares has increased by 3.90% in one year.

Current Share Class	n/a
Shares Outstanding	27.93M
Shares Change (YoY)	+3.90%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	2.42%
Owned by Institutions (%)	3.69%
Float	16.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.50
PB Ratio	1.95
P/TBV Ratio	2.42
P/FCF Ratio	17.61
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.51, with an EV/FCF ratio of 25.63.

EV / Earnings	-41.76
EV / Sales	0.73
EV / EBITDA	16.51
EV / EBIT	n/a
EV / FCF	25.63

Financial Position

The company has a current ratio of 0.82, with a Debt / Equity ratio of 1.20.

Current Ratio	0.82
Quick Ratio	0.43
Debt / Equity	1.20
Debt / EBITDA	7.16
Debt / FCF	11.22
Interest Coverage	0.09

Financial Efficiency

Return on equity (ROE) is -9.67% and return on invested capital (ROIC) is 0.33%.

Return on Equity (ROE)	-9.67%
Return on Assets (ROA)	0.15%
Return on Capital (ROIC)	0.33%
Revenue Per Employee	590.79M
Profits Per Employee	-10.31M
Employee Count	1,033
Asset Turnover	1.04
Inventory Turnover	4.30

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -27.11% in the last 52 weeks. The beta is 0.93, so Ildong Pharmaceutical's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	-27.11%
50-Day Moving Average	12,694.60
200-Day Moving Average	14,192.90
Relative Strength Index (RSI)	34.81
Average Volume (20 Days)	75,678

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ildong Pharmaceutical had revenue of KRW 610.28 billion and -10.65 billion in losses. Loss per share was -401.59.

Revenue	610.28B
Gross Profit	227.24B
Operating Income	1.39B
Pretax Income	-16.26B
Net Income	-10.65B
EBITDA	27.23B
EBIT	1.39B
Loss Per Share	-401.59

Full Income Statement

Balance Sheet

The company has 61.42 billion in cash and 194.90 billion in debt, giving a net cash position of -133.48 billion or -4,778.69 per share.

Cash & Cash Equivalents	61.42B
Total Debt	194.90B
Net Cash	-133.48B
Net Cash Per Share	-4,778.69
Equity (Book Value)	162.55B
Book Value Per Share	5,617.33
Working Capital	-50.88B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 27.33 billion and capital expenditures -9.96 billion, giving a free cash flow of 17.36 billion.

Operating Cash Flow	27.33B
Capital Expenditures	-9.96B
Free Cash Flow	17.36B
FCF Per Share	621.68

Full Cash Flow Statement

Margins

Gross margin is 37.24%, with operating and profit margins of 0.23% and -1.75%.

Gross Margin	37.24%
Operating Margin	0.23%
Pretax Margin	-2.66%
Profit Margin	-1.75%
EBITDA Margin	4.46%
EBIT Margin	0.23%
FCF Margin	2.85%

Dividends & Yields

Ildong Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.90%
Shareholder Yield	-3.90%
Earnings Yield	-3.67%
FCF Yield	5.68%

Stock Splits

The last stock split was on March 5, 2020. It was a forward split with a ratio of 1.05.

Last Split Date	Mar 5, 2020
Split Type	Forward
Split Ratio	1.05

Scores

Ildong Pharmaceutical has an Altman Z-Score of 1.38. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.38
Piotroski F-Score	n/a